QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grim, S. A Articles by Romanelli, F. Search for Related Content PubMed PubMed Citation Articles by Grim, S. A Articles by Romanelli, F.

FORMULARY FORUM

Tenofovir Disoproxil Fumarate

Infectious Diseases Specialty Resident, University of Kentucky, Lexington, KY

Frank Romanelli, PharmD BCPS

Assistant Professor of Pharmacy, Clinical Specialist HIV/AIDS, University of Kentucky

Reprints: Shellee A Grim PharmD, University of Kentucky, 800 Rose St., C117, Lexington, KY 40536-0293, FAX 859/323-2049, E-mail sgrim2{at}uky.edu

OBJECTIVE: To review the pharmacology, virology, pharmacokinetics, efficacy, safety, resistance profile, and clinical use of tenofovir disoproxil fumarate.

DATA SOURCES: A MEDLINE search was performed (1966–August 2002) using the following terms: tenofovir, tenofovir disoproxil fumarate, PMPA (9-(R)-[2-(phosphonomethoxy)propyl]adenine), and Viread. Abstracts from HIV-related meetings were reviewed.

DATA EXTRACTION AND STUDY SELECTION: Publications and meeting abstracts regarding tenofovir were reviewed. The most recent and pertinent items were included.

DATA SYNTHESIS: Tenofovir disoproxil fumarate is a nucleotide prodrug that is diphosphorylated to its active moiety, tenofovir diphosphate. In this form, tenofovir acts as a reverse transcriptase inhibitor to inhibit HIV-1 replication. In clinical trials, tenofovir was effective at suppressing HIV-1 RNA and boosting CD4+ cell counts. Tenofovir has a long intracellular half-life, which permits once-daily dosing. Since tenofovir does not interact with the cytochrome P450 pathway, it exhibits minimal drug interactions, with the exception of didanosine. Compared with other reverse transcriptase inhibitors, tenofovir may have advantages in terms of toxicity and medication adherence profiles. Ongoing studies are also analyzing tenofovir's activity against hepatitis B virus.

CONCLUSIONS: Tenofovir has been shown to be active against HIV-1 in combination with other antiretrovirals. The drug's benefit as a single-agent intensifier of highly active antiretroviral therapy in treatment-experienced patients has been established, and preliminary data for treatment-naïve patients are encouraging.

Key Words: PMPA, tenofovir, Viread

This article has been cited by other articles:

				G. Birkus, N. Kutty, G.-X. He, A. Mulato, W. Lee, M. McDermott, and T. Cihlar Mol. Pharmacol., July 1, 2008; 74(1): 92 - 100. [Abstract] [Full Text] [PDF]

				I. Pandrea, R. M. Ribeiro, R. Gautam, T. Gaufin, M. Pattison, M. Barnes, C. Monjure, C. Stoulig, J. Dufour, W. Cyprian, et al. Simian Immunodeficiency Virus SIVagm Dynamics in African Green Monkeys J. Virol., April 1, 2008; 82(7): 3713 - 3724. [Abstract] [Full Text] [PDF]

				M. R. Blum, G. E. Chittick, J. A. Begley, and J. Zong Steady-State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers J. Clin. Pharmacol., June 1, 2007; 47(6): 751 - 759. [Abstract] [Full Text] [PDF]

				G. Birkus, R. Wang, X. Liu, N. Kutty, H. MacArthur, T. Cihlar, C. Gibbs, S. Swaminathan, W. Lee, and M. McDermott Cathepsin A Is the Major Hydrolase Catalyzing the Intracellular Hydrolysis of the Antiretroviral Nucleotide Phosphonoamidate Prodrugs GS-7340 and GS-9131 Antimicrob. Agents Chemother., February 1, 2007; 51(2): 543 - 550. [Abstract] [Full Text] [PDF]

				M. J. Zapor, K. L. Cozza, G. H. Wynn, G. W. Wortmann, and S. C. Armstrong Antiretrovirals, Part II: Focus on Non-Protease Inhibitor Antiretrovirals (NRTIs, NNRTIs, and Fusion Inhibitors) Psychosomatics, December 1, 2004; 45(6): 524 - 535. [Abstract] [Full Text] [PDF]

				P. L Anderson Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy Ann. Pharmacother., November 1, 2004; 38(11): 1924 - 1934. [Abstract] [Full Text] [PDF]

				J. E. Gallant, S. Staszewski, A. L. Pozniak, E. DeJesus, J. M. A. H. Suleiman, M. D. Miller, D. F. Coakley, B. Lu, J. J. Toole, A. K. Cheng, et al. Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial JAMA, July 14, 2004; 292(2): 191 - 201. [Abstract] [Full Text] [PDF]

				R. J Nestor Correction: tenofovir disoproxil fumarate Ann. Pharmacother., July 1, 2003; 37(7): 1148 - 1148. [Full Text] [PDF]